Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.64 |
| ▸ | BAD | Q92934 | 1/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.60 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.59 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 4/20 | 0.57 |
| ▸ | RXRB | P28702 | 4/20 | 0.57 |
| ▸ | RXRG | P48443 | 1/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189289 | 1.00 | BCL2L1 (0.64) | BCL2L1BADESR2TRIM24TRIM33 | |
| SCHEMBL121809 | 0.86 | KMO (0.68) | ESR2RXRARXRBDCLRE1BKMO | |
| SCHEMBL16166011 | 0.86 | KMO (0.72) | BCL2L1BADTRIM24TRIM33RXRA | |
| SCHEMBL30066684 | 0.86 | KMO (0.72) | BCL2L1BADTRIM24TRIM33RXRA | |
| SCHEMBL3210250 | 0.85 | KMO (0.60) | ESR2RXRARXRBDCLRE1BKMO | |
| SCHEMBL8889438 | 0.84 | PDGFRB (0.55) | BCL2L1BADTRIM24TRIM33RXRA | |
| SCHEMBL29906143 | 0.84 | KMO (0.76) | BCL2L1BADTRIM24TRIM33RXRA | |
| SCHEMBL2346605 | 0.84 | KMO (0.76) | BCL2L1BADTRIM24TRIM33RXRA | |
| SCHEMBL27607318 | 0.83 | TSHR (0.67) | BCL2L1BADTRIM24TRIM33RXRA | |
| SCHEMBL11134357 | 0.83 | MAPT (0.62) | ESR2LMNADCLRE1BTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| US-20220184041-A1 | (AZA)Benzothiazolyl Substituted Pyrazole Compounds | PFIZER INC. (US) | 2022-06-16 | — | — | US | disclosed |
| WO-2022112919-A1 | (AZA)BENZOTHIAZOLYL SUBSTITUTED PYRAZOLE COMPOUNDS | PFIZER INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | disclosed |
| US-20200399282-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| WO-2020128816-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF A BENZOXAZOLE TRANSTHYRETIN STABILIZER AND AN ADDITIONAL THERAPEUTIC AGENT | PFIZER INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| US-20060178438-A1 | Muscarinic agonists | ELI LILLY AND COMPANY (IN) | 2006-08-10 | — | — | US | disclosed |
| US-20060154922-A1 | Muscarinic agonists | ELILILLY AND COMPANY (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
| EP-0357702-A1 | FLUORINATED OLIGOPHENYL DERIVATIVES. | MERCK PATENT GMBH (DE) | 1990-03-14 | — | — | EP | disclosed |
| WO-1989006678-A1 | FLUORINATED OLIGOPHENYL DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154922-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | BCL2L1 3965/4885BAD 2091/4885ESR2 1007/4885 |
| US-20060178438-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | BCL2L1 3965/4885BAD 2091/4885ESR2 1007/4885 |
| US-20200399282-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC4 | BCL2L1 3557/4885BAD 2961/4885ESR2 3919/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | BCL2L1 3426/4885BAD 369/4885ESR2 3141/4885 |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | CHRM1, CHRM3, CHRM2 | BCL2L1 4339/4885BAD 2547/4885ESR2 728/4885 |
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | BCL2L1 783/4885BAD 475/4885ESR2 3633/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | BCL2L1 3789/4885BAD 2905/4885ESR2 37/4885 |
| US-20220184041-A1 | (AZA)Benzothiazolyl Substituted Pyrazole Compounds | TTR, APOB, SERPINB6 | BCL2L1 3097/4885BAD 3897/4885ESR2 3824/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | BCL2L1 4519/4885BAD 3116/4885ESR2 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.